Expertise in
6
conditions

Dr. Margaret V. Ragni

Hematology
5115 Centre Ave, Upmc Cancer Pavillion, 
Pittsburgh, PA 
Expertise in
6
conditions
5115 Centre Ave, Upmc Cancer Pavillion, 
Pittsburgh, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Margaret Ragni is a Hematologist in Pittsburgh, Pennsylvania. Dr. Ragni is highly rated in 6 conditions, according to our data. Her top areas of expertise are Hemophilia A, Blood Clots, Von Willebrand Disease (VWD), Hemophilia B, and Hip Replacement.

Her clinical research consists of co-authoring 160 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Licenses
Specialist in PA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UPMC
  • EPO
  • PPO

Locations

5115 Centre Ave, Upmc Cancer Pavillion, Pittsburgh, PA 15232

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Phase 1, Open-Label Study to Assess the Pharmacokinetics, and Safety and Tolerability of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Adults With Type 2N and 3 Von Willebrand Disease (VWD)
A Phase 1, Open-Label Study to Assess the Pharmacokinetics, and Safety and Tolerability of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Adults With Type 2N and 3 Von Willebrand Disease (VWD)
Enrollment Status: Completed
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drug: Efanesoctocog alfa (BIVV001)
Study Phase: Phase 1
ATHN 9: A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People With Severe Von Willebrand Disease (VWD)
ATHN 9: A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People With Severe Von Willebrand Disease (VWD)
Enrollment Status: Active_not_recruiting
Publish Date: March 12, 2025
A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People With Hemophilia
A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People With Hemophilia
Enrollment Status: Completed
Publish Date: February 12, 2025
Prospective, Randomized Trial Comparing Recombinant Von Willebrand Factor (rVWF) Plus Tranexamic Acid Vs. RVWF Alone to Reduce Postpartum Hemorrhage in Women with Von Willebrand Disease: the VWD-WOMAN Trial
Prospective, Randomized Trial Comparing Recombinant Von Willebrand Factor (rVWF) Plus Tranexamic Acid Vs. RVWF Alone to Reduce Postpartum Hemorrhage in Women with Von Willebrand Disease: the VWD-WOMAN Trial
Enrollment Status: Completed
Publish Date: November 13, 2024
Intervention Type: Drug
Study Drugs: Recombinant Von Willebrand factor, Tranexamic Acid
Study Phase: Phase 3
Prospective, Randomized, Crossover Trial Comparing Recombinant Von Willebrand Factor (rVWF) vs. Tranexamic Acid (TA) to Minimize Menorrhagia in Women With Von Willebrand Disease: The VWD Minimize Study
Prospective, Randomized, Crossover Trial Comparing Recombinant Von Willebrand Factor (rVWF) vs. Tranexamic Acid (TA) to Minimize Menorrhagia in Women With Von Willebrand Disease: The VWD Minimize Study
Enrollment Status: Terminated
Publish Date: July 01, 2024
Intervention Type: Drug
Study Drugs: Von Willebrand Factor, Tranexamic Acid
Study Phase: Phase 3
An Observational Cohort Study of Long-Term Outcomes of Orthotopic Liver Transplantation in People With Hemophilia
An Observational Cohort Study of Long-Term Outcomes of Orthotopic Liver Transplantation in People With Hemophilia
Enrollment Status: Completed
Publish Date: May 10, 2023
Multicenter, Randomized Phase III Inhibitor Prevention Trial, Comparing Eloctate vs. Emicizumab to Prevent Inhibitor Formation in Severe Hemophilia A
Multicenter, Randomized Phase III Inhibitor Prevention Trial, Comparing Eloctate vs. Emicizumab to Prevent Inhibitor Formation in Severe Hemophilia A
Enrollment Status: Terminated
Publish Date: April 11, 2023
Intervention Type: Drug
Study Drugs: Eloctate ITI, Emicizumab
Study Phase: Phase 3
Phase III Multi-Center, Randomized, Controlled Inhibitor Eradication Trial, Comparing Eloctate Immune Tolerance Induction (ITI) Plus Emicizumab vs. Eloctate ITI Alone to Eradicate Inhibitor Formation in Severe Hemophilia A
Phase III Multi-Center, Randomized, Controlled Inhibitor Eradication Trial, Comparing Eloctate Immune Tolerance Induction (ITI) Plus Emicizumab vs. Eloctate ITI Alone to Eradicate Inhibitor Formation in Severe Hemophilia A
Enrollment Status: Terminated
Publish Date: February 21, 2023
Intervention Type: Drug
Study Drugs: Eloctate ITI, Emicizumab
Study Phase: Phase 3
A Longitudinal, Observational Study of Previously Treated Hemophilia Patients Switching Factor Replacement Products
A Longitudinal, Observational Study of Previously Treated Hemophilia Patients Switching Factor Replacement Products
Enrollment Status: Completed
Publish Date: December 09, 2021
Intervention Type: Biological
A Phase 1/2a, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) Profile of a Long Acting Recombinant FVIIa (MOD-5014) in Adult Men With Hemophilia A or B
A Phase 1/2a, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) Profile of a Long Acting Recombinant FVIIa (MOD-5014) in Adult Men With Hemophilia A or B
Enrollment Status: Completed
Publish Date: May 20, 2021
Intervention Type: Drug
Study Phase: Phase 1
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Enrollment Status: Completed
Publish Date: November 10, 2020
Intervention Type: Drug
A Long-Term Follow-Up Study in Subjects With Sever Hemophilia B Who Received Adeno-Associated Viral Vectors Expressing Human Factor IX
A Long-Term Follow-Up Study in Subjects With Sever Hemophilia B Who Received Adeno-Associated Viral Vectors Expressing Human Factor IX
Enrollment Status: Completed
Publish Date: May 15, 2020
A Phase 1 Safety Study in Subjects With Severe Hemophilia B (Factor IX Deficiency) Using a Single-Stranded, Adeno-Associated Pseudotype 8 Viral Vector to Deliver the Gene for Human Factor IX
A Phase 1 Safety Study in Subjects With Severe Hemophilia B (Factor IX Deficiency) Using a Single-Stranded, Adeno-Associated Pseudotype 8 Viral Vector to Deliver the Gene for Human Factor IX
Enrollment Status: Terminated
Publish Date: March 12, 2019
Intervention Type: Biological
Study Phase: Phase 1
View 12 Less Clinical Trials

160 Total Publications

Take five: the story of factor V regulation.
Take five: the story of factor V regulation.
Journal: Blood
Published: July 31, 2025
Similar Doctors
Enrico M. Novelli
Expertise in
9
conditions
Dr. Enrico M. Novelli
Hematology
Expertise in
9
conditions
Dr. Enrico M. Novelli
Hematology

Classical Hematology

3601 Fifth Ave, Falk Building, 3rd Floor, 
Pittsburgh, PA 
 (1.0 miles away)
412-586-9875
Languages Spoken:
English, Italian, Spanish
See accepted insurances
Accepting New Patients

Enrico M. Novelli, MD, is a classical (benign) hematologist, the Chief of the Section of Benign Hematology, and the medical director of the UPMC Adult Sickle Cell Disease Program. Board-certified in hematology, Dr. Novelli received his medical degree from the University of Milan, Italy. He completed his residency in internal medicine and fellowship in hematology-oncology at UPMC. Dr. Novelli specializes in sickle cell anemia and hemoglobinopathies. Dr. Novelli is highly rated in 9 conditions, according to our data. His top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, and Hemolytic Anemia.

Craig Seaman
Expertise in
14
conditions
Dr. Craig Seaman
Hematology
Expertise in
14
conditions
Dr. Craig Seaman
Hematology

Classical Hematology

3601 Fifth Ave, Falk Building, 3rd Floor, 
Pittsburgh, PA 
 (1.0 miles away)
412-586-9875
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Craig Seaman is a Hematologist in Pittsburgh, Pennsylvania. Dr. Seaman is highly rated in 14 conditions, according to our data. His top areas of expertise are Von Willebrand Disease (VWD), Hemophilia A, Blood Clots, and Hemophilic Arthropathy. Dr. Seaman is currently accepting new patients.

Expertise in
40
conditions
Dr. Mounzer Agha
Hematology
Expertise in
40
conditions
Dr. Mounzer Agha
Hematology

Oncology Hematology Association Inc

5115 Centre Ave, Fl 3, 
Pittsburgh, PA 
 (0.1 miles away)
412-235-1020
Languages Spoken:
English
See accepted insurances

Mounzer Agha is a Hematologist in Pittsburgh, Pennsylvania. Dr. Agha is highly rated in 40 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ragni's expertise for a condition
ConditionClose
    View All 11 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile